Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
Adherence · people with asthma
1 finding from 1 review
Exacerbations (OCS) · people with asthma
It is very uncertain whether electronic trackers or reminders (± feedback) changes exacerbations requiring OCS (people with at least 1) WMD of compared with controls (very low certainty).
1 finding from 1 review
Overall mortality · critically ill participants with ALI and ARDS
INO showed no clear difference in overall mortality compared with control group (moderate certainty).
1 finding from 1 review
Overall mortality at 28 days · critically ill participants with ALI and ARDS
INO showed no clear difference in overall mortality at 28 days compared with control group (moderate certainty).
1 finding from 1 review
Mortality in paediatric population (subgroup) · critically ill participants with ALI and ARDS
INO showed no clear difference in mortality in paediatric population (subgroup) compared with control group (moderate certainty).
1 finding from 1 review
RR 0.78 [0.51, 1.18]
185 participants
Moderate
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · critically ill participants with ALI and ARDS
INO probably leads to higher paO2/FiO2 up to 24 hours compared with control group (moderate certainty).
1 finding from 1 review
Oxygenation index (absolute values) after 24 hours of treatment · critically ill participants with ALI and ARDS
INO showed no clear difference in oxygenation index, 24 hours compared with control group (moderate certainty).
1 finding from 1 review
Ventilator‐free days up to day 28 · critically ill participants with ALI and ARDS
INO showed no clear difference in ventilation‐free days, up to 30 days compared with control group (high certainty).
1 finding from 1 review
Incidence of renal impairment · critically ill participants with ALI and ARDS
INO leads to higher renal impairment compared with control group (high certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in mortality (all‐cause) compared with tiotropium (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in hospital admission (all causes) compared with tiotropium (low certainty).
1 finding from 1 review
Exacerbations · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in exacerbation ‐ at 12‐month compared with tiotropium (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 pre‐dose ‐ FEV1 1 year · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
Intervention not reported
Exacerbations requiring oral corticosteroids 48 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring oral corticosteroids 48 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life (AQLQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review